Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

AKAN vs DBVT vs ALKS vs TLRY vs CGC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AKAN
Akanda Corp.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • GB
Market Cap$874K
5Y Perf.-100.0%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1690.08T
5Y Perf.+24.1%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.83B
5Y Perf.+33.0%
TLRY
Tilray Brands, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$648M
5Y Perf.-28.4%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$119M
5Y Perf.-98.5%

AKAN vs DBVT vs ALKS vs TLRY vs CGC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AKAN logoAKAN
DBVT logoDBVT
ALKS logoALKS
TLRY logoTLRY
CGC logoCGC
IndustryDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$874K$1690.08T$5.83B$648M$119M
Revenue (TTM)$2M$0.00$1.56B$1.17B$294M
Net Income (TTM)$-31M$-168M$153M$-2.95B$-327M
Gross Margin-43.7%65.4%28.0%22.8%
Operating Margin-6.3%12.3%-266.0%-24.1%
Forward P/E24.5x
Total Debt$353K$22M$70M$451M$348M
Cash & Equiv.$4M$194M$1.12B$304M$114M

AKAN vs DBVT vs ALKS vs TLRY vs CGCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AKAN
DBVT
ALKS
TLRY
CGC
StockMar 22May 26Return
Akanda Corp. (AKAN)1000.0-100.0%
DBV Technologies S.… (DBVT)100124.1+24.1%
Alkermes plc (ALKS)100133.0+33.0%
Tilray Brands, Inc. (TLRY)10071.6-28.4%
Canopy Growth Corpo… (CGC)1001.5-98.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: AKAN vs DBVT vs ALKS vs TLRY vs CGC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Tilray Brands, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
AKAN
Akanda Corp.
The Healthcare Pick

AKAN plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Income Pick

DBVT is the clearest fit if your priority is income & stability.

  • Dividend streak 0 yrs, beta 1.26
Best for: income & stability
ALKS
Alkermes plc
The Long-Run Compounder

ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • -12.0% 10Y total return vs TLRY's -75.2%
  • Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.00, current ratio 3.55x
  • 9.8% margin vs AKAN's -19.6%
Best for: long-term compounding and sleep-well-at-night
TLRY
Tilray Brands, Inc.
The Growth Play

TLRY is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 4.8%, EPS growth -6.5%, 3Y rev CAGR 12.5%
  • 4.8% revenue growth vs DBVT's -100.0%
  • +11.6% vs AKAN's -62.5%
Best for: growth exposure
CGC
Canopy Growth Corporation
The Healthcare Pick

Among these 5 stocks, CGC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTLRY logoTLRY4.8% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs AKAN's -19.6%
Stability / SafetyALKS logoALKSBeta 1.00 vs TLRY's 2.04, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)TLRY logoTLRY+11.6% vs AKAN's -62.5%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs AKAN's -380.2%, ROIC 18.9% vs -7.5%

AKAN vs DBVT vs ALKS vs TLRY vs CGC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AKANAkanda Corp.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
TLRYTilray Brands, Inc.
FY 2025
Cannabis Segment
36.1%$331M
Distribution Revenue
29.6%$271M
Beverage Alcohol Business
27.7%$253M
Wellness Business
6.6%$60M
CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0

AKAN vs DBVT vs ALKS vs TLRY vs CGC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGCGC

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AKAN's -19.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
RevenueTrailing 12 months$2M$0$1.6B$1.2B$294M
EBITDAEarnings before interest/tax-$8M-$112M$212M-$3.0B-$32M
Net IncomeAfter-tax profit-$31M-$168M$153M-$2.9B-$327M
Free Cash FlowCash after capex-$7M-$151M$392M-$94M-$86M
Gross MarginGross profit ÷ Revenue-43.7%+65.4%+28.0%+22.8%
Operating MarginEBIT ÷ Revenue-6.3%+12.3%-2.7%-24.1%
Net MarginNet income ÷ Revenue-19.6%+9.8%-2.5%-111.0%
FCF MarginFCF ÷ Revenue-4.4%+25.1%-8.1%-29.3%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%+28.2%+3.0%+20.9%
EPS Growth (YoY)Latest quarter vs prior year+88.4%+91.5%-4.1%+70.7%+83.8%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — AKAN and DBVT and TLRY each lead in 1 of 3 comparable metrics.
MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
Market CapShares × price$873,882$1690.08T$5.8B$648M$119M
Enterprise ValueMkt cap + debt − cash-$3M$1690.08T$4.8B$795M$291M
Trailing P/EPrice ÷ TTM EPS-0.10x-0.75x24.47x-0.16x-0.27x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.01x
Price / SalesMarket cap ÷ Revenue1.04x3.95x0.57x0.61x
Price / BookPrice ÷ Book value/share0.11x0.65x3.25x0.24x0.33x
Price / FCFMarket cap ÷ FCF12.14x
Evenly matched — AKAN and DBVT and TLRY each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-15 for AKAN. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs TLRY's 4/9, reflecting strong financial health.

MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
ROE (TTM)Return on equity-15.1%-130.2%+8.8%-136.5%-43.1%
ROA (TTM)Return on assets-3.8%-89.0%+5.4%-100.6%-29.5%
ROICReturn on invested capital-7.5%+18.9%-66.2%-10.2%
ROCEReturn on capital employed-3.0%-145.7%+14.2%-78.1%-12.4%
Piotroski ScoreFundamental quality 0–954745
Debt / EquityFinancial leverage0.08x0.13x0.04x0.22x0.72x
Net DebtTotal debt minus cash-$3M-$172M-$1.0B$147M$235M
Cash & Equiv.Liquid assets$4M$194M$1.1B$304M$114M
Total DebtShort + long-term debt$352,814$22M$70M$451M$348M
Interest CoverageEBIT ÷ Interest expense-47.93x-189.82x32.30x-89.43x-7.79x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TLRY leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $1 for AKAN. Over the past 12 months, TLRY leads with a +1157.1% total return vs AKAN's -62.5%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.0% vs AKAN's -82.5% — a key indicator of consistent wealth creation.

MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
YTD ReturnYear-to-date+174.4%+3.6%+23.8%-42.8%-6.7%
1-Year ReturnPast 12 months-62.5%+100.5%+15.2%+1157.1%-17.2%
3-Year ReturnCumulative with dividends-99.5%+18.1%+13.2%+100.0%-91.6%
5-Year ReturnCumulative with dividends-100.0%-68.3%+61.7%-63.0%-99.5%
10-Year ReturnCumulative with dividends-100.0%-87.1%-12.0%-75.2%-94.4%
CAGR (3Y)Annualised 3-year return-82.5%+5.7%+4.2%+26.0%-56.2%
TLRY leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than TLRY's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs AKAN's 14.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
Beta (5Y)Sensitivity to S&P 5001.46x1.26x1.00x2.04x1.95x
52-Week HighHighest price in past year$185.80$26.18$36.60$15.70$2.38
52-Week LowLowest price in past year$1.41$7.53$25.17$0.35$0.84
% of 52W HighCurrent price vs 52-week peak+14.5%+75.3%+95.6%+35.4%+46.6%
RSI (14)Momentum oscillator 0–10064.747.460.536.851.1
Avg Volume (50D)Average daily shares traded2.7M252K2.2M4.7M10.3M
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: DBVT as "Buy", ALKS as "Buy", TLRY as "Hold", CGC as "Hold". Consensus price targets imply 1203.6% upside for CGC (target: $14) vs 31.5% for ALKS (target: $46).

MetricAKAN logoAKANAkanda Corp.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcTLRY logoTLRYTilray Brands, In…CGC logoCGCCanopy Growth Cor…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHold
Price TargetConsensus 12-month target$46.33$46.00$10.00$14.47
# AnalystsCovering analysts15282026
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 1 (Total Returns). 1 tied.

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

AKAN vs DBVT vs ALKS vs TLRY vs CGC: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is AKAN or DBVT or ALKS or TLRY or CGC a better buy right now?

For growth investors, Tilray Brands, Inc.

(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -61. 3% for Akanda Corp. (AKAN). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — AKAN or DBVT or ALKS or TLRY or CGC?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -100. 0% for Akanda Corp. (AKAN). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus AKAN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — AKAN or DBVT or ALKS or TLRY or CGC?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Tilray Brands, Inc. 's 2. 04β — meaning TLRY is approximately 104% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — AKAN or DBVT or ALKS or TLRY or CGC?

By revenue growth (latest reported year), Tilray Brands, Inc.

(TLRY) is pulling ahead at 4. 8% versus -61. 3% for Akanda Corp. (AKAN). On earnings-per-share growth, the picture is similar: Akanda Corp. grew EPS 100. 0% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, AKAN leads at 172. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — AKAN or DBVT or ALKS or TLRY or CGC?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -489. 6% for Akanda Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -523. 8% for AKAN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — AKAN or DBVT or ALKS or TLRY or CGC?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is AKAN or DBVT or ALKS or TLRY or CGC better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, TLRY: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between AKAN and DBVT and ALKS and TLRY and CGC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AKAN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

TLRY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.